Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D
Department of Neurological and Psychiatric Sciences, University of Florence, Italy.
Clin Neuropharmacol. 1996 Dec;19(6):497-506. doi: 10.1097/00002826-199619060-00003.
We treated, in a preliminary open trial, 31 patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on computed tomography (CT) with a 90-mg daily dose of nimodipine for a period as long as 1 year (minimum: 96 days, maximum: 424 days), to study the safety and possible effects on functional and cognitive conditions throughout this period. Of the 29 patients who had been followed for at least 9 months, most (82%) remained stable or improved as evaluated by the Global Deterioration Scale. A significant improvement was observed in the total Sandoz Clinical Assessment Geriatric scale score (44.66 +/- 7.17 at baseline vs. 36.86 +/- 9.34 at exit, analysis-of-variance time effect, p < 0.0001). These data indicate that nimodipine, chronically administered in patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on CT, is safe and might have beneficial effect, to be confirmed by a randomized trial.
在一项初步开放性试验中，我们对31例出现认知障碍、进行性双侧运动功能障碍且计算机断层扫描（CT）显示有脑白质疏松症的患者，给予每日90毫克的尼莫地平治疗，为期长达1年（最短：96天，最长：424天），以研究在此期间其安全性以及对功能和认知状况的可能影响。在29例随访至少9个月的患者中，根据总体衰退量表评估，大多数（82%）病情保持稳定或有所改善。在桑多兹临床老年评估量表总分上观察到显著改善（基线时为44.66±7.17，结束时为36.86±9.34，方差分析时间效应，p<0.0001）。这些数据表明，对于出现认知障碍、进行性双侧运动功能障碍且CT显示有脑白质疏松症的患者长期服用尼莫地平是安全的，且可能具有有益效果，这有待随机试验予以证实。
